Vuba aha, Ascentage Pharma yatangaje ko umuti wayo mushya wa Bcl-2 selective inhibitor lisaftoclax (APG-2575) wemejwe n’Ikigo cy’Igihugu cy’Ubushinwa gishinzwe Ibikoresho by’Ubuvuzi (NMPA) mu kuvura abarwayi bakuru bafite kanseri y’amaraso idakira/lymphoma ntoya (CLL/SLL) bamaze guhabwa nibura ubuvuzi bumwe burimo imiti igabanya ubukana bwa tyrosine kinase (BTK), ibi bikaba bituma lisaftoclax iba umuti wa mbere wa Bcl-2 inhibitor wemerewe kandi uhabwa uburenganzira bwo kugurisha abarwayi bafite CLL/SLL mu Bushinwa, n’umuti wa kabiri wa Bcl-2 inhibitor wemejwe ku isi yose.
Lisaftoclax ni umuti mushya kandi ukoreshwa mu kanwa, ugabanya Bcl-2 mu buryo budasanzwe, wakozwe na Ascentage Pharma kugira ngo uvure abarwayi bafite kanseri binyuze mu guhagarika poroteyine irwanya apoptotike ya Bcl-2 bityo ugasubiza inzira isanzwe yo kuvura kanseri mu turemangingo twa kanseri. Mu igeragezwa ryakozwe, lisaftoclax yagaragaje ubushobozi bwinshi bwo kuvura kanseri nyinshi zo mu maraso n'ibibyimba bikomeye, cyane cyane muri CLL/SLL, haba mu buryo bumwe cyangwa mu buryo buvanze.
Uku kwemezwa gushingiye ku byavuye mu bushakashatsi bw’ingenzi bwakozwe mu cyiciro cya kabiri (APG2575CC201) bwagenewe gusuzuma imikorere n’umutekano wa lisaftoclax monotherapy ku barwayi ba CLL/SLL yasubitse cyangwa yangiritse, aho igipimo rusange cyo gusubiza (ORR) ari cyo cya mbere cyavuyemo. Lisaftoclax yagaragaje imikorere myiza kandi ORR yujuje ibisabwa byagenwe ku barwayi bavuwe mbere na BTK inhibitors cyangwa immunochemotherapy. Byongeye kandi, lisaftoclax yagaragaje umutekano mwiza nta ndwara ya tumor-lysis syndrome (TLS) ibaho mu gihe cy’ubushakashatsi, uburozi bw’amaraso buke bwashoboraga gukemuka, kandi uburozi butari ubwo mu maraso bwari mu cyiciro cya 1-2.
CLL/SLL ni kanseri y’amaraso iterwa n’uturemangingo tw’uturemangingo twa B dukuze. Yibasira cyane cyane abantu bakuze, aho abantu barenga 100.000 bavurwa buri mwaka ku isi.1. Mu Bushinwa, aho igipimo cy’ubwiyongere bwa CLL/SLL kiri hasi ugereranyije n’icyo mu bihugu by’iburengerazuba, iyi ndwara ikomeje kwiyongera cyane, aho abantu bakiri bato batangira kuyirwara kandi ikaba ikomeye cyane2. Nk’uburyo bw’ibanze bwo kuvura CLL/SLL ku rwego rwa mbere, imiti igabanya ubukana bwa BTK yazamuye cyane umusaruro w’ubuvuzi ku barwayi. Ariko, imiti igabanya ubukana bwa BTK iracyahura n’ibibazo bitandukanye nko kuba nta bushobozi bwo gusubiza ibintu mu buryo bwimbitse, ibyago byinshi byo kongera kurwara mu gihe cyo hagati no mu gihe kirekire, uburozi no kutihanganirwa bijyana no kuvurwa igihe kirekire; bityo, hakenewe uburyo bwiza kandi bunoze bwo kuvura abarwayi ba CLL/SLL.
Gukoresha imiti igabanya ubukana bwa Bcl-2 byarushijeho guhindura uburyo bwo kuvura CLL/SLL. Uburyo bwo gukurura apoptosis Bcl-2, bukunze kwigaragaza cyane mu ndwara zitandukanye za kanseri zifata amaraso, cyane cyane CLL/SLL, ni uburyo bw'ingenzi butuma uturemangingo twa kanseri twirinda apoptosis. Ariko, kuvumbura Bcl-2 igabanya ubukana nk'intego yo kuvura biragoye cyane bitewe nuko uburyo ikora bushingiye ku mikoranire ya poroteyine na poroteyine (PPI). Uburyo Bcl-2 ifatanamo ni bunini, bigatuma bigora abafite molecule nto kugira ingaruka zo gukumira. Byongeye kandi, poroteyine ya Bcl-2 iherereye kuri mitochondria, ifite imiterere ibiri ya membrane, iri mu bice bigoye kandi bigoye cyane by'uturemangingo kuko bisaba ko imiti ibanza kwinjira mu ruhu rw'uturemangingo mbere yuko ikomeza gukora ku ruhu rw'uturemangingo. Mbere y'ibi, nta muti wa Bcl-2 wari wemerewe kuvura CLL/SLL mu Bushinwa. Uku kwemererwa kwa lisaftoclax kuzuza icyuho mu kuvura CLL/SLL, bitanga icyizere gishya ku barwayi benshi mu gihugu.
Kugeza ubu, haracyari igeragezwa ryinshi ry’ikoranabuhanga rishya rirwanya kanseri mu Bushinwa rishaka abarwayi. Inama ku miti mishya n’ikoranabuhanga, ushobora kuvugana n’Ishami Mpuzamahanga ry’Ibitaro bya Oncology bya Beijing mu Karere k’Amajyepfo.
Nimero ya Terefone: 4008803716
Email：myimmnet@163.com
Igihe cyo kohereza: 15 Nyakanga-2025